TD Cowen raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 beat and they expect the company to stay independent but believes its pipeline is being overlooked.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $36 from $30 at Stifel
- Exelixis price target raised to $29 from $25 at Barclays
- Exelixis price target raised to $38 from $37 at Piper Sandler
- Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
- Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments